Synthetic Biology and My Cell has an app for that:
Some day we might go from my "cell phone" has an app for that to my "cell" has and app for that. This might sound like science fiction, but it might not be as hard as you think.
1/ I spent many years studying the cellular communications pathways inside our cells. These are the pathways that take signals from the receptors which receive signals from the outside and transmit them to the nucleus.
2/ The signal is transmitted to the nucleus and turns on genes. Those changes result in an output of some kind in the form of cell behavior. It wasn't until I started to study Synthetic Biology did it makes sense.
3/ If you translate the operations of cells into those we understand from electronics, it makes so much more sense. The DNA is the operating system. Its 3 billion bases long of information stored inside the nucleus.
4/ The receptors of the cells are like inputs. Just like if you push a button on your remote it activates pathways in the circuits that delivery that signal to the TV that changes the channel. The circuit can go to many different places and activate or shut off different systems.
5/ Learning how to understand and transfer these circuit into those like a computer could help computers, AI and ML to design and develop cellular circuits. This could lead to the seamless integration of biotech and technology.
6/ With synthetic biology, gene editing, and new delivery systems, we could go from my phone has an app for that to my cell has an app for that.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
I had to break this down into the business side and the science as my notes are too big for one thread.
1/ Their mission is cell programming. They are not a fully vertical platform from source to customer. They are built to program cells for other companies that sell to the customers.
2/ That means they also have suppliers. Key public suppliers to them are $TWST for DNA and $BLI for workflow machines. They then sell the cells they design to their customers.
I had to break this down into the business side and the science as my notes are too big for one thread.
1/ $DNA has a multi tier share structure which is very different from most companies in the market. They concentrate the vast majority of the voting power to the insiders.
2/ The class A shares are the common stock and count for 1 vote. The class B shares are for insiders and rewards for insiders. They get 10 votes per share and convert to class A shares if they are sold or the person quits or is fired.
1/ The pluripotent stem cell is capable of developing into many types of cells. We use to believe that cells could only develop in one direction, but a scientist named Shinya Yamanaka discovery how to take a mitotic cell and revert it back into a stem cell.
2/ This process was celled induced Pluripotent Stem cells. The ability to turn any cell back into a stem cell just by treating it with a combination of various transcription factors.
A look at the editing that goes into CAR-T and CAR-NK cell therapies.
1/ The first major challenge to any cell therapy is to overcome the rejection of the cells by host immunity. All cells have a MHC code on them that labels them as "self".
2/ When a person's MHC code does not match someone else, you can get the cells attacking the patient or the patients immune cells attacking the donor cells.
For Whom does the Cell Toll? (A History of cell therapies)
A look at the history of cell therapies and editing.
1/ Engineering cells for cell therapies brings together the best of synthetic biology and genomics. Its about taking cells and reprogramming them into a therapy to treat disease.
2/ My focus in this space has been highly geared toward immune cells like T and NK cells. I will look at the evolution of cell therapies and where we are going.